home / stock / rzlt / rzlt news

RZLT News and Press, Rezolute Inc. From 09/14/23

Stock Information
Company Name: Rezolute Inc.
Stock Symbol: RZLT
Market: NASDAQ
Website: rezolutebio.com
Menu
RZLT RZLT Quote RZLT Short RZLT News RZLT Articles RZLT Message Board
Get RZLT Alerts

News, Short Squeeze, Breakout and More Instantly...
RZLT - Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial r...
RZLT - Rezolute to Participate in Upcoming Investor Conferences in September

REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced tha...

RZLT - Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4 : 30 p.m. ET REDWOOD CITY, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biop...

RZLT - Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in the treatment of diabetic eye disease, including diabetic retinopathy (DR) ...
RZLT - Rezolute GAAP EPS of -$0.30 in-line

2023-05-12 06:55:26 ET Rezolute press release ( NASDAQ: RZLT ): Q3 GAAP EPS of -$0.30 in-line. Cash and cash equivalents totaled $33.7 million and investments in marketable debt securities totaled $95.5 million as of March 31, 2023. For further details see: Rezol...

RZLT - Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial re...

RZLT - Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, yesterday hosted a virtual key...
RZLT - Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

REDWOOD CITY, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to transform the treatment paradigms of devastating metabolic diseases, will host a virtual ev...

RZLT - Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

Initiated Phase 2 proof-of-concept study of RZ402 Anticipate initiation of global Phase 3 clinical study for RZ358 in mid 2023 REDWOOD CITY, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing ...

RZLT - Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

REDWOOD CITY, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that the Compan...
Previous 10 Next 10